Business Context and Reporting Period
Company: Bionano Genomics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 4, 2024
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $10.0 million (before fees and expenses).
- Offering Price: $1.145 per share of Common Stock plus accompanying Warrant; $1.144 per Pre-Funded Warrant plus accompanying Warrant.
- Securities Issued:
- 6,536,682 shares of Common Stock.
- Pre-funded warrants to purchase up to 2,196,944 shares of Common Stock.
- Warrants to purchase up to 8,733,626 shares of Common Stock.
- Placement Agent Fee: 6.0% of gross proceeds.
- Warrant Terms: Exercise price of $1.02 per share; immediately exercisable; five-year expiration.
- Pre-Funded Warrant Terms: Exercise price of $0.001 per share; immediately exercisable.
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt levels. These operational metrics are not included in this specific 8-K report.
Material Changes and Use of Proceeds
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. The Company plans to use the net proceeds for:
- General corporate purposes.
- Working capital.
- Research and development expenses.
- Repayment or redemption of existing indebtedness.
- Capital expenditures.
Guidance, Outlook, and Risks
Outlook: The offering is expected to close on or about April 8, 2024, subject to customary closing conditions.
Risks and Contingencies:
- Completion of the offering is subject to satisfaction of closing conditions.
- Forward-looking statements regarding the use of proceeds are subject to uncertainties in the research and product development process.
- Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the report.
Important Facts for Investor Verification
- Verify the final closing date and actual net proceeds after deducting the 6.0% placement agent fee and other expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Confirm the impact of the new share issuance and warrant exercises on total outstanding shares and potential future dilution.
- Check subsequent filings for the actual application of proceeds, specifically regarding the repayment of existing indebtedness.